Senseonics Holdings, Inc. (SENS) SEC Filings & Earnings Calls

European revenue timing normalization risk; Europe expected ~20% of FY revenue but Q2 was only $1.9M vs $1.7M prior year

“revenue outside the U.S. was $1.9 million compared to $1.7 million in the prior year period, an increase of approximately 12%, reflecting the timing of tender updates in Europe as the Company continued its commercial transition from Ascensia.” · word for word

Operating expenses rising faster than revenue; SG&A $32.9M vs $9.7M YoY due to commercial integration

“Second quarter 2026 selling, general and administrative expenses were $32.9 million, compared to $9.7 million for the second quarter of 2025, related primarily to the commercial integration and European transition.” · word for word

Debt Covenant Compliance Risk

“If we fail to comply with these covenants, we could be in default under the facility, which could result in the acceleration of all outstanding indebtedness thereunder and materially adversely affect our financial condition and ability to continue as a going concern.” · word for word

Financing Dependency

“Future borrowings under the agreement are subject to the satisfaction of certain terms and conditions and, with respect to the final $60.0 million, the approval of Hercules’s investment committee.” · word for word

Operating Losses

“We incurred total net loss of $(69.1) million and $(78.6) million for the years ended December 31, 2025 and 2024, respectively.” · word for word

Integration risk and potential dilution from acquisition-related costs.

“Asset purchases closed; no financial terms disclosed.”

European Asset Purchase Conditions

“The closing of each of the European Asset Purchases is subject to the satisfaction or waiver of customary closing conditions, including the obtaining of certain regulatory clearances, consents or non-objection with respect to the transfer of tender contracts and the completion of certain required labor and employment processes. There can be no assurance that” · word for word

Debt Covenant Compliance

“If we fail to comply with these covenants, we could be in default under the facility, which could result in the acceleration of all outstanding indebtedness thereunder and materially adversely affect our financial condition and ability to continue as a going concern.” · word for word

Future Financing Need

“If we are unable to access the full amount of the facility, we may not have sufficient liquidity to fund our operations and may need to seek additional financing on terms that may be less favorable, or we may not be able to obtain additional financing at all.” · word for word

Net loss increased significantly due to commercial transition costs; SG&A expenses rose $22.5M YoY.

“Net loss was $32.3 million ... compared to net loss of $14.3 million ... selling, general and administrative expenses increased by $22.5 million year-over-year.”

Dependence on successful European launch and transition from Ascensia distributor.

“Currently launching Eversense 365 in Europe with first insertions in Sweden in April ... transition of Eversense commercialization from Ascensia in Europe.” · word for word

Dilution from equity offering: 8M shares + 8M pre-funded warrants

“8,000,000 shares of the Company's common stock and 8,000,000 pre-funded warrants”

Significant net loss and cash burn

“net loss between $31 million and $33 million” · word for word

Dilution Risk from Authorized Share Increase

“Proposal to increase authorized shares from 70M to 140M, which would result in dilution of the earnings per share and voting rights of current holders of common stock.”

Revenue Concentration Risk

“Net revenue from the Company's distribution arrangement with Ascensia accounted for 53% of total net revenues for the year ended December 31, 2025.” · word for word

Going Concern / Capital Need

“The Company has not generated significant profit from the sale of products and its ability to generate revenue and achieve profitability largely depends on the Company's ability to successfully expand the commercialization of Eversense... These activities will require significant uses of working capital over the next several years.” · word for word

Commercial transition risk from Ascensia to in-house operations may cause disruption.

“Executed agreements with Ascensia Diabetes Care to take back commercialization and distribution of Eversense beginning January 1, 2026.” · word for word

High SG&A spending due to DTC marketing and consignment sales may pressure margins.

“Selling, general and administrative expenses increased by $10.9 million year-over-year to $19.8 million from $8.9 million for the fourth quarter of 2024.” · word for word

Dependence on regulatory approvals for EU launch and Gemini trial completion.

“Received CE Mark approval for Eversense 365 in the European Union; Secured IDE approval from the FDA to commence a pivotal trial for Gemini sensor.”

Going Concern Uncertainty

“Our management has concluded that the capital considerations required to assume Eversense commercialization and distribution responsibilities...raise substantial doubts regarding our ability to continue as a going concern for the next twelve months” · word for word

Commercial Transition Execution Risk

“The transition of commercial responsibility for Eversense to Senseonics in European markets is subject to the finalization and execution of definitive agreements with Ascensia and an uncertain government approval process.” · word for word

Dependence on Single Product

“Our current business strategy is highly dependent on the successful commercialization of Eversense and achieving and maintaining market acceptance.” · word for word

Patent Litigation Risk

“In May 2024, the Company received notice and accepted service of a civil complaint...styled Cellspin Soft, Inc. vs. Senseonics Holdings, Inc., and Ascensia Diabetes Care Holdings AG...alleging patent infringement of three patents.” · word for word

Transition of commercialization from Ascensia may cause operational disruptions.

“Transition of commercial operations from Ascensia; uncertainties in finalizing integration and commercial terms.”

Regulatory and tariff risks could impact supply chain and costs.

“Effects of tariffs mentioned in risk factors.”

Preliminary financials subject to audit adjustments.

“Preliminary unaudited financial information subject to change upon audit.”

Commercial transition risk from Ascensia back to Senseonics

“Signed memorandum of understanding with Ascensia Diabetes Care and collaborating with Ascensia to transition commercial responsibility for Eversense back to Senseonics.” · word for word

Continued net loss and cash burn

“Net loss of $19.5 million; cash used in operations 2025 expected ~$60 million.”

Dependence on regulatory approvals for EU launch

“We continue to anticipate receiving CE Mark approval for Eversense 365 by the end of the year.” · word for word

Going concern risk

“the Company has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.” · word for word

Customer concentration

“For the three months ended September 30, 2025 and 2024, sales to Ascensia accounted for 48% and 78% of total revenue, respectively.” · word for word

Transition risk from Ascensia

“The transition of commercial responsibility for Eversense to Senseonics is subject to the finalization and execution of a definitive agreement with Ascensia and, for certain European countries, an uncertain government approval process.” · word for word

Tariff exposure

“Should additional tariffs be imposed specifically targeting medical device components, our production costs could rise significantly” · word for word

Limited commercialization experience

“We have limited operating history as a commercial-stage company and may face difficulties encountered by companies early in their commercialization” · word for word